These assessments collectively offer a comprehensive evaluation of the AAV vectors, ensuring that your AAVs meet even the most stringent standards for safe and effective gene therapy applications.
Extensive Capabilities
Safety Assurance
Timely Results
Expert Guidance
Uncompromising Quality
Tailored Solutions
We offer more than 40 standarized AAV quality assays.
| Category | SKU# | Test | Method | Turnaround Time (Calendar Day) |
| Titration | AAVQC001-001 | AAV Genome Titration <ddPCR> | ddPCR | 5 |
| AAVQC001-002 | Custom ddPCR probe and primer synthesis | – | 5-7 | |
| AAVQC001-003 | AAV Capsid Titration | ELISA | 5 | |
| AAVQC001-004 | Infectious Titer <TCID50> | Serial Dilution and qPCR | 21 | |
| Genome Integrity | AAVQC002-001 | AAV Genomic Integrity <CE> | CE | 5 |
| AAVQC002-002 | AAV Genomic Sequencing <TGS> | 3rd Generation Sequencing | 5-10 | |
| AAVQC002-003 | AAV Identity by Sanger sequencing | Sanger sequencing | 3-5 | |
| AAVQC002-004 | Alkaline Gel Electrophoresis | Agarose gels | 6 | |
| Capsid characterization, purity and aggregation | AAVQC003-001 | AAV Empty Capsid Rate <AUC> | AUC to analyze empty capsid rate | 5 |
| AAVQC003-002 | TEM (5 pictures) +report | TEM | 3-5 | |
| AAVQC003-003 | DLS (Dynamic light scattering) | Dynamic light scattering | 5 | |
| AAVQC003-004 | AAV Capsid Peptide Mapping | HPLC-MS/MS | 21 | |
| AAVQC003-005 | Capsid Protein Molecular Weight and Ratio | RP-HPLC-MS | 21 | |
| AAVQC003-006 | Capsid purity Analysis <SDS-PAGE> | SDS-PAGE with Silver Staining | 2-3 | |
| AAVQC003-007 | Capsid purity Analysis <SDS-PAGE> | SDS-PAGE with Coomassie Blue Staining | 5 | |
| AAVQC003-008 | Capsid purity Analysis <CE-SDS> | CE-SDS | 5 | |
| AAVQC003-009 | Purity Analysis <AEC-HPLC> | AEC-HPLC | 5 | |
| AAVQC003-010 | Purity and Aggregation Analysis <SEC-HPLC> | SEC-HPLC | 5 | |
| Contamination | AAVQC004-001 | Residual Host HEK293 Cell DNA Quantification | qPCR | 5 |
| AAVQC004-002 | Residual HEK293 Host Cell DNA Sizing | qPCR | 5 | |
| AAVQC004-003 | Residual Plasmid DNA | ddPCR | 5 | |
| AAVQC004-004 | Residual E1A | ddPCR | 5 | |
| AAVQC004-005 | Residual Host Cell Protein | ELISA | 5 | |
| AAVQC004-006 | Residual BSA | ELISA | 5 | |
| AAVQC004-007 | Residual Nuclease | ELISA | 5 | |
| AAVQC004-008 | Residual Affinity Ligands | ELISA | 5 | |
| AAVQC004-009 | Residual PEI | HPLC | 5 | |
| AAVQC004-010 | Residual Tween20 | HPLC | 5 | |
| AAVQC004-011 | Residual Triton X100 | HPLC | 5 | |
| AAVQC004-012 | Residual Iodixanol | HPLC | 5 | |
| AAVQC004-013 | Residual Poloxamer 188 | HPLC | 5 | |
| AAVQC004-015 | Residual Triton Analysis（bundle with endo removal) | HPLC | 5 | |
| Safety | AAVQC005-001 | Endotoxin removal | Triton | 2-3 |
| AAVQC005-002 | Sterility test | Innoculation | 14-20 | |
| AAVQC005-003 | Mycoplasma detection | Gel | 2-3 | |
| AAVQC005-004 | Endotoxin test | LAL | 3 | |
| AAVQC005-005 | Quantitative Endotoxin test | Kinetic Chromogenic Assays | 3 | |
| AAVQC005-006 | Bioburden Test | Plate count method | 5 | |
| AAVQC005-007 | Mycoplasma detection by qPCR | qPCR | 2-3 | |
| AAVQC005-008 | Replication Competent AAV (rcAAV) Analysis | Infection on Permissive Cells | 21 |
(Scroll down to see more)
AAV Genome Titer by ddPCR
Provides precise quantification of viral genome copies, ensuring accurate assessment of viral load. This is essential for determining effective dosages and maintaining batch-to-batch consistency in gene therapy applications.
AAV genome titer by ddPCR
AAV Genome Integrity by CE
Evaluates the structural integrity of AAV genomes by identifying fragmentation or degradation. These measures are key determinants of AAV stability, efficacy, and safety.
AAV genome integrity analysis by CE
AAV Genome Sequencing by Nanopore
Offers detailed analysis of the AAV genome by detecting mutations, insertions, and deletions. This comprehensive genome evaluation ensures the fidelity and stability of the AAV vector and is essential for therapeutic use.
Nanopore sequencing reads depth from 5‘ ITR to 3’ ITR
AAV Empty Capsid Rate Test by AUC
Measures the proportion of empty versus full capsids, which is critical for determining the potency and immunogenicity of a therapy. AUC is the gold-standard method for measuring empty capsid rate and helps to ensure the delivery of high-quality viral vectors.
AAV empty capsid rate analysis by AUC
Replication Competent AAV (rcAAV) Analysis
Detects and quantifies replication-competent AAV, which is essential for ensuring the safety of gene therapies. Minimizing rcAAV contamination is necessary to prevent unwanted viral replication in patients.
AAV Packaging Services
Ranging from pilot to industrial-scale AAV packaging for both in vitro and in vivo studies.
READ MORE
Off the Shelf AAV Products
We offer a wide catalogue of pre-made AAVs for a multitude of research needs.
READ MORE